



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Patrick E. Garrett
Jeffrey T. Helvey
Heldi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Albert L. Ferro
Donald R. Banowit
Peter A. Jackman
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Brian J. Del Buono
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest
Daniel A. Klein

Jason D. Lisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller Wright LuAnne M. DeSantis Ann E. Summerfield Aric W. Ledford Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Nicole D. Dretar Ted J. Ebersolle Laura A. Vogel Michael J. Mancuso Bryan S. Wade Aaron L. Schwartz

Jason D. Fisenbern

Shannon A. Carroli* Wesley W. Jones* Matthew E. Kelley* Michelle K. Holoubek* Marsha A. Rose*

Registered Patent Agents
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse Christopher J. Walsh Liliana Di Nola-Baron Peter A. Socarras Jeffrey Mills

Of Counsel
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

November 1, 2005

WRITER'S DIRECT NUMBER: (202) 772-8679
INTERNET ADDRESS: TSHEA@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Art Unit 1636

Mail Stop: Amendment

Re:

U.S. Utility Patent Application

Application No. 10/633,697; Filed: August 5, 2003

For: Glycosylation Engineering of Antibodies for Improving Antibody-

Dependent Cellular Cytotoxicity

Inventors:

UMAÑA et al.

Our Ref:

1975.0010005/TJS

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Credit Card Payment Form (PTO-2038) in the amount of \$3,350.00 to cover excess claims;
- 2. Fee Transmittal Form (PTO/SB/17);
- 3. Second Preliminary Amendment Under 37 C.F.R. § 1.115; and
- 4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents November 1, 2005 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER GOLDSTEIN & FOX P.L.L.C.

Timothy J. Shea, Jr. Attorney for Applicants

Registration No. 41,306

TJS/slw Enclosures

460660_1.DOC

NOV 0 1 2005 W

Equivalent to Form PTO/SB/17 (12-04)

Approved for use through 07/31/2006.

Under the Paperwork Reduction	Act of 1995	no persons are required to	especial a collection	of information unle	ess it displays a v	alid OMB control number	
Effectiv Fees pursuant to the Consolidate	Complete if Known						
	Application Numb	per 10/633,	10/633,697				
FEE TRANSMITTAL For FY 2005			Filing Date		August 5, 2003		
			First Named Inve		Pablo UMAÑA		
Applicant claims small entity status. See 37 CFR 1.27			Examiner Name	David (David Guzo		
			Art Unit	1636	1636 1975.0010005/TJS		
TOTAL AMOUNT OF PAYM	ENI (\$	3,350.00	Attorney Docket	No. 1975.001	10005/TJS		
METHOD OF PAYMENT (check all that apply)							
Check X Credit Card Money Order None Other (please identify):							
X Deposit Account Deposit Account Number: 19-0036 Deposit Account Name: Sterne, Kessler, Goldstein & Fox P.L.L.C.							
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)							
Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee							
Charge any additional fee(s) or underpayments of fee(s) X Credit any overpayments							
under 37 CFR 1.16 and 1.17 WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
·	FILING FEES SEAF			EXAMINATIO			
Application Type	Fee (\$)	<u>Small Entity</u> <u>Fee (\$) </u>	Small Entity S) Fee (\$)		II Entity e (\$)	Fees Paid (\$)	
Utility	300	150 500	250	200 1	00		
Design	200	100 100	50	130	65 -		
Plant	200	100 300	150	160	80 -		
Reissue	300	150 500	250	600 3	00 -	<u>.</u>	
Provisional	200	100 0	0	0	0 -		
2. EXCESS CLAIM FEES Small Entity							
Fee Description Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent Fee (\$) Fee (\$) 50 25							
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent 200 100							
Multiple dependent claims 360 180							
<u>Total Claims</u> <u>Extra Claims</u> <u>Fee (\$)</u> <u>Fee Paid (\$)</u> <u>Multiple Dependent Claims</u>							
HP = highest number of total cla		, if greater than 20		360.00	0	141	
Indep. Claims							
HP = highest number of indeper		paid for, if greater than 3	<u> </u>				
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity)							
for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$)							
- 100 =			(round up to a wh			_=	
4. OTHER FEE(S) Non-English Specification, \$130 fee (no small entity discount)							
Other:							
	// /	/ //	= = = = = = = = = = = = = = = = = = = =				
SUBMITTED BY	(1.1/	Registration No.		Telephone	(000) 000	
	X	my 1	(Attorney/Agent)	41,306	-	(202) 371-2600	
lame (Print/Type) Timothy	J. Shea, J	r. /			Date 7/0	rember 1, 200	

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

UMAÑA et al.

Appl. No.: 10/633,697

Filed: August 5, 2003

For: Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular

Cytotoxicity

Confirmation No.: 5455

Art Unit: 1636

Examiner: Guzo, D.

Atty. Docket: 1975.0010005/TJS

Second Preliminary Amendment

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Preliminary to any action on the merits, Applicants submit the following amendments and remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, a complete listing of all of the claims:
- in ascending order;
- with status identifiers; and
- with markings in the currently amended claims;
- (C) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying 01 FC:1202 3350.00 0P this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net

addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.